About 4 results.

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

FDA finds mystery 'deficiencies' with <span class='lighter'>Neos</span>' long-acting Ritalin on the eve of approval
2015-10-20 Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

吉利德12亿美元收购Nimbus Therapeutics子公司Nimbus Apollo,拓展肝病研发管线

吉利德12亿美元收购Nimbus <span class='lighter'>Therapeutics</span>子公司Nimbus Apollo,拓展肝病研发管线
2016-04-07 丙肝药霸主吉利德近年来一直致力于通过收购拓展自身的研发管线。近日吉利德宣布将收购Nimbus Therapeutics全资子公司Nimbus Apollo及其旗下一个在研乙酰辅酶A...

不选择癌症药物研发,Ovid Therapeutics为何要专注罕见神经系统疾病领域?

不选择癌症药物研发,Ovid <span class='lighter'>Therapeutics</span>为何要专注罕见神经系统疾病领域?
2016-09-27 十年前,只有2个抗癌药物项目在研究如何调节人体免疫系统,使之更好地攻击肿瘤细胞的方法。“但研究人员注意到,肿瘤并没有缩小,而是在不断增长。”知名医药...

Prime Therapeutics urges FDA to keep current, consistent naming conventions for biologics

2014-09-09 Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.